De Novo MET-amplified NSCLC treated with savolitinib achieved remarkable tumor regression: a case report and review of literature
Abstract Primary MET amplification is an infrequent tumorigenic driver gene alteration identified in pulmonary neoplasms. Data on the effectiveness of MET-tyrosine kinase inhibitor (TKI) therapy in de novo MET amplification are relatively scarce, and there remains a dearth of empirical evidence supp...
Saved in:
| Main Authors: | Jin Sheng, Juan Jiao, Na Yan, Hongming Pan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer
2025-02-01
|
| Series: | Journal of Cancer Research and Clinical Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1007/s00432-025-06132-x |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Copy number gain of MET gene with low level in a metastatic lung adenocarcinoma patient represents response to salvage treatment with savolitinib and osimertinib: a case report
by: Jian Wang, et al.
Published: (2025-04-01) -
Expert Consensus on Diagnosis and Treatment of NSCLC with MET Abnormalities
(2025 Version)
by: Jun CHEN, et al.
Published: (2025-02-01) -
The potential role of next-generation sequencing in identifying MET amplification and disclosing resistance mechanisms in NSCLC patients with osimertinib resistance
by: Xiao Xiao, et al.
Published: (2024-10-01) -
Crizotinib Treatment for Lorlatinib-resistant MET-amplified EML4-ALK-fusion Positive Advanced Lung Adenocarcinoma: A Case Report
by: Xinyi WANG, et al.
Published: (2024-12-01) -
NGS coverage accurately predicts MET and HER2 (ERBB2) gene amplifications in a real-world non-small cell lung cancer cohort
by: Adam Kowalewski, et al.
Published: (2025-07-01)